Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Open Access
- 1 July 1991
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 174 (1) , 35-44
- https://doi.org/10.1084/jem.174.1.35
Abstract
Decay-accelerating factor (DAF) is a glycosyl-phosphatidylinositol (GPI)-anchored membrane protein that protects cells from complement-mediated damage by regulation of the C3 convertase. To investigate the role of the GPI anchor in the function of DAF, the cDNA encoding human DAF was expressed by transfection in Chinese hamster ovary (CHO) cells. Testing of these DAF transfectants in an antibody plus human complement-mediated cytotoxicity assay demonstrated that DAF protects these cells from cytotoxicity, and that the level of protection increases with expression of surface DAF. A cDNA construct encoding a transmembrane version of DAF (DAF-TM) protects CHO transfectants from cytotoxicity with equal efficiency to DAF. This DAF-TM construct used the TM and cytoplasmic domains of membrane cofactor protein (MCP); an alternate TM version of DAF constructed with the TM and cytoplasmic domains of HLA-B44 showed equivalent protection. The protection from cytotoxicity involved a decrease in the deposition of C3 on the cell, consistent with the effect of DAF on the C3 convertase. A second pair of anchor variants, MCP and a GPI-anchored construct, MCP-PI, were also equivalent in their complement protection. The equivalent function of GPI-anchored and TM versions of a protein was not expected based on the hypothesized increased lateral mobility of GPI-anchored proteins, which should confer a functional advantage in contacting ligand, in this case, C3b or C4b, on the cell surface. These data suggest either that GPI-anchored and TM versions of a protein have equal lateral mobility in the membrane, or else that increased lateral mobility is not advantageous to DAF or MCP in carrying out their complement inhibitory roles. Furthermore, DAF and MCP demonstrated approximately equal protection of cells from complement-mediated cytotoxicity, suggesting that DAF and MCP provide overlapping levels of protection to cells against damage mediated by the complement system.Keywords
This publication has 40 references indexed in Scilit:
- Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositolMolecular Immunology, 1989
- Expression of membrane interleukin 1 by fibroblasts transfected with murine pro-interleukin 1 alpha cDNA.Proceedings of the National Academy of Sciences, 1988
- Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP). Evidence for inclusion in the multigene family of complement-regulatory proteins.The Journal of Experimental Medicine, 1988
- Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.Proceedings of the National Academy of Sciences, 1987
- Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipidBiochemistry, 1986
- Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor.The Journal of Immunology, 1986
- Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.The Journal of Experimental Medicine, 1986
- Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.The Journal of Immunology, 1986
- Decay-accelerating factor is present on cultured human umbilical vein endothelial cells.The Journal of Experimental Medicine, 1986
- SURFACE-MEMBRANE EXPRESSION BY HUMAN-BLOOD LEUKOCYTES AND PLATELETS OF DECAY-ACCELERATING FACTOR, A REGULATORY PROTEIN OF THE COMPLEMENT-SYSTEM1985